DexCom (NASDAQ: DXCM) reported Q3 EPS of $0.45, $0.02 better than the analyst estimate of $0.43. Revenue for the quarter came in at $994.2 million versus the consensus estimate of $990.44 million.

GUIDANCE:

DexCom sees FY2024 revenue of $4-4.05 billion, versus the consensus of $4.01 billion.

• Revenue of approximately $4.00 - 4.05 billion (11 - 13% organic growth2)
• Non-GAAP Gross Profit Margin of approximately 63%
• Non-GAAP Operating Margin of approximately 20%
• Adjusted EBITDA Margin of approximately 29%

For earnings history and earnings-related data on DexCom (DXCM) click here.